查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1832336

血型分型市場（按產品類型、技術、最終用戶和應用）—全球預測 2025-2032

Blood Group Typing Market by Product Type, Technology, End User, Application - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年血型鑑定市場規模將成長至 67.6 億美元，複合年成長率為 8.05%。

主要市場統計數據
基準年2024年 36.3億美元
預計2025年 39.3億美元
預測年份：2032年 67.6億美元
複合年成長率（%） 8.05%

對不斷發展的血型狀況的權威介紹，強調臨床安全優先事項、技術轉型以及實驗室和輸血服務的運作要求

血型鑑定領域處於臨床安全、實驗室效率和技術創新的交匯點。自動化、試劑化學和分子平台的進步正在逐步將常規工作流程從手動、勞動密集型任務轉變為整合系統，從而減少人為錯誤並加快週轉時間。同時，對輸血安全和精準醫療的日益重視，也使得強大的血型鑑定解決方案在血庫、臨床實驗室和醫院診斷部門的戰略重要性日益凸顯。

在此背景下，相關人員正在應對複雜的遺留基礎設施、新興分子診斷技術和不斷變化的監管預期。與實驗室資訊系統的互通性以及對抗血清和試劑紅血球的有效供應鏈管理仍然是營運的優先事項。此外，人口趨勢、周產期護理需求以及對感染疾病增強的警覺性等因素，持續推動先進篩檢和輸血前檢測通訊協定的採用。隨著實驗室和血液服務機構重新評估其套件，在整合能夠顯著改善患者安全性的技術的同時，平衡成本、可靠性和合規性至關重要。

全面回顧再形成血型的重大變革，包括自動化、分子整合、試劑進步和可互通的測試系統

近年來，一場變革性的轉變正在重新定義血型分型的執行和管理方式。儀器平台的自動化已從理想目標轉變為大批量生產中心的實際需求，從而減少了人工干預並實現了結果的一致性。同時，聚合酵素鏈鎖反應等分子技術已將血型分型的範圍擴展到血清學之外，為複雜的抗原譜和產前篩檢應用提供了更高的特異性。

此外，試劑創新促進了抗血清製劑和經驗證的篩檢細胞的開發，從而提高了檢測穩定性並減少了可疑結果的發生。與實驗室資訊系統的整合簡化了報告、可追溯性和合規性工作流程，使其逐漸成為預期功能，而非差異化因素。這種轉變促使人們更加關注儀器支援服務和生命週期管理，以確保執行時間和校準標準符合臨床吞吐量需求。總而言之，這些發展正在創造一個更具彈性、互通性且診斷更精細的血型分析環境，既支持常規輸血實踐，也支持專門的臨床場景。

深入分析近期美國關稅調整如何影響整個血型檢測供應鏈的籌資策略、供應商多樣化和庫存彈性

關稅變化和貿易政策調整將對實驗室和血液服務籌資策略、供應鏈彈性和成本結構產生即時和持續的影響。美國近期的關稅行動促使採購部門和採購負責人重新評估其進口設備、試劑和耗材的採購途徑。這些調整促使供應商更積極地多元化，許多組織正在尋求替代供應商、區域分銷商或國內製造合作夥伴，以減輕進口相關成本波動的風險。

此外，關稅環境促使庫存管理加強，並與供應商簽訂了更嚴格的合約條款，以保持服務的連續性。對於一些相關人員，跨境物流日益複雜，促使他們投資長期供應協議，並與主要供應商進行聯合預測，以防止運輸延誤和海關相關的中斷。同時，臨床使用的法規合規性和合格要求限制了關鍵試劑和系統的快速替換，因此需要精心安排過渡和檢驗方案。因此，採購團隊必須在應對力與對經過檢驗、符合臨床要求的產品的嚴格需求之間取得平衡。

基於細分的關鍵洞察揭示了產品類型、技術、最終用戶需求和臨床應用將如何決定血型檢測的採購和部署策略

細分洞察揭示了臨床需求、技術能力和服務期望在哪些方面交匯，從而影響採購和部署決策。實驗室會根據產品類型評估自動血型儀和凝膠卡分析儀等設備的通量及其與現有工作流程的兼容性，而抗血清試劑、試劑紅血球和篩檢細胞等試劑組合則會根據穩定性、特異性和監管文件進行評判。互補軟體和服務（包括實驗室資訊系統整合、支援和維護）對價值主張的提案日益凸顯，因為它們能夠簡化報告流程並實現長期業務連續性。

在考慮技術時，組織會權衡流式細胞技術的高靈敏度抗原檢測、用於常規分型的凝膠離心的穩健性、微孔盤凝集的高通量篩檢能力，以及用於基因分型的分子即時PCRPCR 平台）。技術的選擇取決於臨床複雜性、所需的通量以及產前或輸血醫學病例所需的分子解析度水平。最終用戶細分進一步明確了採用模式：政府和私人血庫優先考慮捐贈者篩檢效率和冷鏈物流，醫院獨立臨床實驗室強調工作流程整合和周轉時間，私立和公立醫院優先考慮可靠的輸血前檢測和新生兒篩檢能力。

以應用為重點的分析強調，捐贈者篩檢（包括血型鑑定和傳染病篩檢）需要擴充性且經過驗證的系統，這些系統能夠在捐贈活動和集中採集設施中持續運作。新生兒篩檢需要能夠快速檢驗途徑並最大程度減少假陽性的檢測方法和工作流程。輸血前檢測強調交叉試驗在時間敏感的臨床環境中的可靠性和相容性。在所有領域，設備選擇、試劑穩定性、技術選擇和服務協議之間的相互作用決定了臨床表現和長期運作的永續性。

從區域觀點解釋供應鏈彈性、監管多樣性和醫療保健基礎設施如何影響全球市場的血型採用模式

區域動態影響整個血型價值鏈的採購選擇、監管導向和夥伴關係模式。在美洲，臨床實驗室和血液服務機構通常青睞高通量血液中心和遵循既定監管路徑的整合自動化系統。這種環境支持採用成熟的血清學平台和不斷發展的分子檢測方法，以補充輸血安全計畫。同時，該地區的戰略採購擴大考慮國內製造能力和區域分銷網路，以緩解供應鏈摩擦。

歐洲、中東和非洲地區管理體制和基礎設施水準參差不齊，既帶來了機遇，也帶來了挑戰。該地區的一些市場優先考慮高度檢驗的試劑系統和跨境醫療保健網路的標準化通訊協定，而其他市場則投資於可在資源受限環境中部署的可擴展技術。公共和私營相關人員的合作計劃在推廣新生兒篩檢和輸血前工作流程的最佳實踐方面發揮關鍵作用。

在亞太地區，人口趨勢和不斷擴大的醫療保健覆蓋範圍正在推動對集中檢測服務和區域參考中心的投資增加。這推動了對可擴展至多站點營運的模組化儀器平台以及能夠確保可靠配送和低溫運輸管理的試劑供應商的需求。在整個地區，本地支援能力、監管透明度和供應鏈韌性對於技術和服務的長期採用和維持仍然至關重要。

競爭動態分析突顯了成熟的診斷製造商、專業試劑製造商、軟體整合商和創新新參與企業在血型生態系中的作用

血型檢測領域的競爭態勢取決於成熟診斷設備製造商、專業試劑製造商以及敏捷軟體和服務公司之間的平衡。成熟的儀器供應商憑藉著檢驗的平台、認證的服務網路以及與高容量血液中心和醫院實驗室的長期合作關係，保持優勢。這些公司投資於產品生命週期管理和法規遵從性，提供將儀器與校準試劑和維護合約捆綁在一起的綜合方案，以確保可預測的臨床性能。

同時，專業試劑供應商和契約製造製造商正致力於提供能夠提高試劑穩定性、降低批次間差異並促進臨床實驗室驗證工作的產品。軟體供應商和系統整合在實現實驗室資訊系統連接、電子報告和品管監控方面變得越來越重要。新興企業公司正在透過新型分子檢測、數位PCR工作流程和雲端分析進行創新，而成熟公司則正在加速其研發和夥伴關係策略。採購主管必須綜合考慮臨床檢驗數據、服務能力、供應連續性保證以及支援與現有實驗室IT生態系統整合的能力來評估潛在供應商。

為產業領導者提供切實可行的建議，重點在於互通性、供應商多樣化、預測性維護、平衡分子整合和相關人員協作

產業領導者應採取一系列切實可行的優先事項，使臨床需求與營運現實和策略成長目標一致。首先，優先投資可互通的系統，以促進儀器平台與實驗室資訊系統之間的無縫整合，減少人工抄錄錯誤，並加快結果報告速度。其次，制定強力的供應商多元化策略，包括經審查的區域經銷商和替代試劑供應商，以緩解供應鏈中斷和關稅相關的不確定性，同時保持合規性和驗證的嚴謹性。

第三，擴大服務和維護契約，在可行的情況下納入預測性維護能力和遠距離診斷，最大限度地延長設備運作，減少被動干預的需求。第四，將分子基因分型方法納入複雜病例和產前篩檢的工作流程，同時在常規、高容量場景中保留血清學方法，最佳化成本效益和診斷解析度。第五，加強與臨床相關人員和監管機構的合作，簡化新檢測方法的驗證途徑，並確保程序變更符合病人安全標準。透過採取這些措施，各組織可以提高韌性，促進技術創新的應用，並維持輸血安全和實驗室性能的高標準。

清楚概述了嚴格的相關人員主導的調查方法，該方法結合了定性專家參與、技術基礎評估和供應鏈情境分析來檢驗見解

這些見解背後的調查方法依賴於一種結構化方法，該方法結合了原始研究和二手資料，以確保分析的嚴謹性和實踐相關性。與實驗室主任、採購經理、血庫負責人和臨床病理學家的交流，提供了關於儀器性能、試劑可靠性和​​服務期望的現場觀點。這些定性資訊與平台功能的技術評估、監管文件審查以及技術採用趨勢分析相結合，從而全面整體情況營運重點和臨床需求。

此外，我們還進行了產品和工作流程評估，以比較血清學和分子檢測方法的功能，並專注於互通性、通量和驗證要求。透過相關人員訪談和情境分析評估了供應鏈和採購流程，以評估應對關稅和物流變化的韌性策略。在整個過程中，我們專注於跨多個資料來源和相關人員類型的三角測量結果，以最大程度地減少偏差，並確保為臨床和機構決策者提供切實可行的建議。

結論證實，策略整合、供應鏈彈性和協作創新對於提高輸血安全和實驗室績效至關重要

總而言之，血型分型領域正在經歷一場務實的變革，其特點是自動化程度不斷提高、分子檢測能力不斷擴展，並更加重視供應鏈的韌性和互通性。輸血安全、新生兒篩檢和可靠的捐血者篩檢等臨床需求持續推動著對經過臨床檢驗、運作永續且以強大服務框架為基礎的解決方案的需求。隨著實驗室和血液服務機構應對不斷變化的資費、監管複雜性和技術選擇，那些優先考慮檢驗、供應商可靠性和自適應採購的組織將最有能力提供一致、以患者為中心的結果。

展望未來，診斷製造商、試劑供應商、軟體整合商和臨床相關人員之間的持續合作對於將創新轉化為日常實踐至關重要。透過將投資與臨床工作流程的實際情況和監管期望相結合，相關人員可以確保技術進步不僅能提高診斷準確性，還能增強輸血操作及相關臨床項目的效率和安全性。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 採用基於次世代定序的血型基因分型平台來加強輸血安全性和相容性測試
  • 在緊急和嚴重監護環境中整合人工智慧分析的照護現場血型檢測設備的成長
  • 增加對基於微陣列的高通量血液抗原篩檢技術的投資，以實現最佳的供體-受體匹配
  • 智慧型手機血凝試驗的出現，可用於偏遠醫療機構的分散血型測定
  • 監管部門推廣使用無細胞 DNA 檢測平台進行非侵入性胎兒 RhD 基因分型，以降低同種免疫風險
  • 整合區塊鏈技術，實現跨醫院和輸血網路的安全、可追溯的血型資料管理
  • 高容量臨床實驗室採用完全整合的血型分析儀實現從樣本到結果的自動化

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第8章 血型分型市場（依產品類型）

  • 裝置
    • 自動血型測定裝置
    • 凝膠卡分析儀
  • 試劑
    • 抗血清試劑
    • 試劑紅血球
    • 篩檢細胞
  • 軟體和服務
    • LIS 整合
    • 支援和維護

9. 血型分型市場（依技術）

  • 流式細胞技術
  • 凝膠離心
  • 微孔盤凝集反應
  • PCR
    • 數位PCR
    • 即時PCR

第 10 章 血型分型市場（依最終使用者）

  • 血庫
    • 政府血庫
    • 私人血庫
  • 臨床實驗室
    • 醫院附設檢查室
    • 獨立研究機構
  • 醫院和診斷中心
    • 私立醫院
    • 公立醫院

第11章血型分型市場的應用

  • 捐贈者篩檢
    • 血型
    • 傳染病篩檢
  • 新生兒篩檢
  • 輸血前檢測

第12章 血型分型市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 血型分型市場（依人群）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 血型分型市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Ortho Clinical Diagnostics, Inc.
    • Abbott Laboratories
    • Thermo Fisher Scientific Inc.
    • Grifols, SA
    • Bio-Rad Laboratories, Inc.
    • Immucor, Inc.
    • Sysmex Corporation
    • BioMerieux SA
    • Quotient Limited
    • Fujirebio Holdings, Inc.
Product Code: MRR-437D459582E9

The Blood Group Typing Market is projected to grow by USD 6.76 billion at a CAGR of 8.05% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.63 billion
Estimated Year [2025] USD 3.93 billion
Forecast Year [2032] USD 6.76 billion
CAGR (%) 8.05%

An authoritative introduction to the evolving blood group typing landscape highlighting clinical safety priorities, technological transitions, and operational imperatives within laboratory and transfusion services

The landscape of blood group typing sits at the intersection of clinical safety, laboratory efficiency, and technological innovation. Advancements in automation, reagent chemistry, and molecular platforms have progressively shifted routine workflows away from manual, labor-intensive tasks toward integrated systems that reduce human error and accelerate turnaround times. In parallel, rising emphasis on transfusion safety and precision medicine has elevated the strategic importance of robust typing solutions across blood banks, clinical laboratories, and hospital diagnostic units.

Against this backdrop, stakeholders are navigating a complex mix of legacy infrastructure, emerging molecular diagnostics, and evolving regulatory expectations. Interoperability with laboratory information systems and the need for effective supply chain management for antisera and reagent red blood cells remain operational priorities. Furthermore, the confluence of demographic trends, perinatal care imperatives, and heightened infectious disease vigilance continues to drive adoption of advanced screening and pretransfusion testing protocols. As laboratories and blood services reassess their toolkits, the imperative is to balance cost, reliability, and regulatory compliance while embracing technologies that deliver measurable improvements in patient safety.

A comprehensive review of the major transformative shifts reshaping blood group typing including automation, molecular integration, reagent advancements, and interoperable laboratory systems

Recent years have seen transformative shifts that are redefining how blood group typing is performed and managed. Automation in instrument platforms has transitioned from an aspirational goal to a practical necessity for high-volume centers, enabling consistent results with reduced manual intervention. Concurrently, molecular techniques such as polymerase chain reaction methodologies are expanding the scope of typing beyond serology, offering higher specificity for complex antigen profiles and prenatal screening applications.

In addition, reagent innovation-spanning antisera formulations and validated screening cells-has enhanced assay stability and reduced incidence of equivocal results. Integration with laboratory information systems has matured into an expected capability rather than a differentiator, streamlining reporting, traceability, and compliance workflows. These shifts are accompanied by an increasing emphasis on support services and lifecycle management for instruments, ensuring that uptime and calibration standards meet clinical throughput demands. Taken together, these developments are producing a more resilient, interoperable, and diagnostically sophisticated blood typing environment that supports both routine transfusion operations and specialized clinical scenarios.

A detailed analysis of how recent United States tariff adjustments have influenced procurement strategies, supplier diversification, and inventory resilience across blood group typing supply chains

Tariff changes and trade policy adjustments can have immediate and downstream effects on procurement strategies, supply chain resilience, and cost structures for laboratories and blood services. In the context of recent tariff movements in the United States, purchasing departments and procurement officers have been prompted to re-evaluate sourcing routes for imported instruments, reagents, and consumables. These adjustments have fostered more deliberate supplier diversification, with many organizations seeking alternative vendors, regional distributors, or domestic manufacturing partners to mitigate exposure to import-related cost volatility.

Moreover, the tariff environment has incentivized tighter inventory management and more rigorous vendor contract terms to preserve service continuity. For some stakeholders, the increased complexity in cross-border logistics led to investment in longer-term supply agreements and collaborative forecasting with key suppliers to protect against shipment delays and customs-related disruptions. At the same time, regulatory conformity and qualification requirements for clinical use have constrained rapid substitution of critical reagents or systems, necessitating carefully sequenced transitions and validation protocols. Consequently, procurement teams must balance responsiveness to trade shifts with the uncompromising need for validated, clinically compliant products.

Key segmentation-driven insights that illuminate how product type, technology, end-user demands, and clinical applications collectively dictate procurement and deployment strategies in blood group typing

Segmentation insights reveal where clinical demand, technological capabilities, and service expectations converge to shape purchasing and deployment decisions. Based on product type, laboratories evaluate instruments such as automated blood typers and gel card analyzers for throughput and compatibility with existing workflows, while reagent portfolios covering antisera reagents, reagent red blood cells, and screening cells are judged on stability, specificity, and regulatory documentation. Complementary software and services, including laboratory information system integration and support and maintenance offerings, are increasingly central to value propositions because they enable streamlined reporting and long-term operational continuity.

When considering technology, organizations weigh the trade-offs between flow cytometry's high-sensitivity antigen detection, gel centrifugation's robustness for routine typing, microplate agglutination's high-throughput screening capacity, and molecular PCR approaches that encompass both digital PCR and real-time PCR platforms for genotyping. The choice of technology is driven by clinical complexity, required throughput, and the level of molecular resolution needed for prenatal or transfusion medicine cases. End-user segmentation further clarifies adoption patterns: government and private blood banks prioritize donor screening efficiency and cold-chain aligned reagent logistics; hospital-based and independent clinical laboratories emphasize workflow integration and turnaround times; and private and public hospitals focus on reliable pretransfusion testing and newborn screening capabilities.

Application-focused analysis underscores that donor screening, including blood typing and infectious disease screening, demands scalable, validated systems that can operate consistently at donor drives and centralized collection sites. Newborn screening requires assays and workflows that minimize false positives while enabling rapid confirmatory pathways. Pretransfusion testing emphasizes crossmatch reliability and compatibility determination under time-constrained clinical settings. Across all segments, the interplay between instrument selection, reagent robustness, technology choice, and service agreements determines both clinical performance and long-term operational sustainability.

Regional perspectives that explain how supply chain resilience, regulatory diversity, and healthcare infrastructure are shaping adoption patterns for blood group typing across global markets

Regional dynamics influence procurement choices, regulatory navigation, and partnership models across the entire blood group typing value chain. In the Americas, clinical laboratories and blood services often favor integrated automation that aligns with high-throughput blood centers and well-established regulatory pathways; this environment supports adoption of both mature serological platforms and evolving molecular methods that complement transfusion safety programs. Meanwhile, strategic purchasing in the region is increasingly informed by considerations of domestic manufacturing capability and regional distribution networks to reduce supply chain friction.

In Europe, the Middle East, and Africa region, heterogeneous regulatory regimes and variable infrastructure levels create both opportunities and challenges. Some markets within this region prioritize highly validated reagent systems and standardized protocols for transnational healthcare networks, while others are investing in scalable technologies that can be deployed in resource-constrained settings. Interoperability and compliance with regional standards frequently drive supplier selection, and collaborative initiatives across public and private stakeholders play a key role in disseminating best practices for newborn screening and pretransfusion workflows.

Within the Asia-Pacific region, demographic trends and expanding healthcare coverage are prompting increased investment in centralized laboratory services and regional reference centers. This has elevated demand for modular instrument platforms that can be scaled across multi-site operations, as well as for reagent suppliers that can ensure reliable distribution and cold-chain management. Across all regions, local support capabilities, regulatory clarity, and supply chain resilience remain pivotal in determining how technologies and services are adopted and sustained over time.

An analysis of competitive dynamics highlighting the roles of established diagnostic manufacturers, reagent specialists, software integrators, and innovative newcomers in the blood group typing ecosystem

Competitive dynamics in the blood group typing domain are defined by a balance between established diagnostic manufacturers, specialized reagent producers, and agile software and services firms. Established instrument vendors maintain advantage through validated platforms, certified service networks, and long-term relationships with high-volume blood centers and hospital laboratories. These players invest in product lifecycle management and regulatory compliance, offering comprehensive packages that bundle instruments with calibrated reagents and maintenance contracts to ensure predictable clinical performance.

At the same time, specialized reagent manufacturers and contract producers focus on improving reagent stability, reducing lot-to-lot variability, and providing products that ease validation efforts for clinical laboratories. Software providers and systems integrators are increasingly critical for enabling laboratory information system connectivity, electronic reporting, and quality control monitoring. Emerging companies and startups bring innovation through novel molecular assays, digital PCR workflows, or cloud-enabled analytics, prompting incumbents to accelerate their own R&D and partnership strategies. For procurement leaders, the imperative is to evaluate potential suppliers on a combination of clinical validation data, service capability, supply continuity guarantees, and the ability to support integration with existing laboratory IT ecosystems.

Actionable recommendations for industry leaders focused on interoperability, supplier diversification, predictive maintenance, balanced molecular integration, and stakeholder collaboration

Industry leaders should pursue a set of actionable priorities that reconcile clinical demands with operational realities and strategic growth objectives. First, prioritize investments in interoperable systems that facilitate seamless integration between instrument platforms and laboratory information systems to reduce manual transcription errors and accelerate result reporting. Second, develop robust supplier diversity strategies that include vetted regional distributors and alternative reagent sources to mitigate supply chain disruptions and tariff-related uncertainties while preserving compliance and validation rigor.

Third, expand service and maintenance agreements to include predictive maintenance capabilities and remote diagnostics where feasible, thereby maximizing instrument uptime and reducing the need for reactive interventions. Fourth, incorporate molecular genotyping methods into workflows for complex cases and prenatal screening while retaining serological techniques for routine, high-volume scenarios to optimize both cost-effectiveness and diagnostic resolution. Fifth, strengthen collaboration with clinical stakeholders and regulatory bodies to streamline validation pathways for new assays and to ensure that procedural changes are aligned with patient safety standards. By adopting these measures, organizations can improve resilience, enable innovation adoption, and sustain high standards of transfusion safety and laboratory performance.

A clear overview of the rigorous, stakeholder-driven research methodology combining qualitative expert engagement, technical platform assessments, and supply chain scenario analyses to validate insights

The research methodology underpinning these insights relies on a structured blend of primary and secondary approaches to ensure analytical rigor and practical relevance. Engagements with laboratory directors, procurement managers, blood bank leaders, and clinical pathologists provided ground-level perspectives on instrument performance, reagent reliability, and service expectations. These qualitative inputs were synthesized with technical evaluations of platform capabilities, regulatory documentation reviews, and analyses of technology adoption dynamics to create a comprehensive picture of operational priorities and clinical needs.

In addition, product and workflow assessments were conducted to compare functionality across serological and molecular techniques, with attention to interoperability, throughput, and validation requirements. Supply chain and procurement processes were examined through stakeholder interviews and scenario analysis to assess resilience strategies in the face of tariff and logistics shifts. Throughout the process, emphasis was placed on triangulating findings across multiple data sources and stakeholder types to minimize bias and ensure that recommendations remain actionable for decision-makers operating in clinical and institutional contexts.

A decisive conclusion affirming that strategic integration, supply chain resilience, and collaborative innovation are essential for advancing transfusion safety and laboratory performance

In conclusion, the field of blood group typing is undergoing a pragmatic evolution characterized by greater automation, expanded molecular capabilities, and an elevated focus on supply chain resilience and interoperability. Clinical imperatives for transfusion safety, newborn screening, and reliable donor screening continue to drive demand for solutions that are clinically validated, operationally sustainable, and supported by strong service frameworks. As laboratories and blood services navigate tariff changes, regulatory complexity, and technological choice, the organizations that emphasize validated integration, supplier reliability, and adaptive procurement will be best positioned to deliver consistent patient-centered outcomes.

Moving forward, continued collaboration between diagnostic manufacturers, reagent suppliers, software integrators, and clinical stakeholders will be essential to translate innovation into routine practice. By aligning investments with clinical workflow realities and regulatory expectations, stakeholders can ensure that technological advances not only improve diagnostic precision but also enhance the efficiency and safety of transfusion services and related clinical programs.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of next-generation sequencing-based blood group genotyping platforms for enhanced transfusion safety and compatibility testing
  • 5.2. Growth in point-of-care blood typing devices integrating AI-driven analysis in emergency and critical care settings
  • 5.3. Rising investment in microarray-based high-throughput blood antigen screening technologies for optimal donor-recipient matching
  • 5.4. Emergence of smartphone-enabled hemagglutination assays for decentralized blood group typing in remote healthcare facilities
  • 5.5. Regulatory push for non-invasive fetal RhD genotyping through cell-free DNA testing platforms to reduce alloimmunization risk
  • 5.6. Integration of blockchain technology for secure and traceable blood type data management across hospital and transfusion networks
  • 5.7. Shift toward automation with fully integrated sample-to-result blood group analyzers in high-volume clinical laboratories

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Blood Group Typing Market, by Product Type

  • 8.1. Instruments
    • 8.1.1. Automated Blood Typers
    • 8.1.2. Gel Card Analyzers
  • 8.2. Reagents
    • 8.2.1. Antisera Reagents
    • 8.2.2. Reagent Red Blood Cells
    • 8.2.3. Screening Cells
  • 8.3. Software & Services
    • 8.3.1. LIS Integration
    • 8.3.2. Support & Maintenance

9. Blood Group Typing Market, by Technology

  • 9.1. Flow Cytometry
  • 9.2. Gel Centrifugation
  • 9.3. Microplate Agglutination
  • 9.4. PCR
    • 9.4.1. Digital PCR
    • 9.4.2. Real-Time PCR

10. Blood Group Typing Market, by End User

  • 10.1. Blood Banks
    • 10.1.1. Government Blood Banks
    • 10.1.2. Private Blood Banks
  • 10.2. Clinical Laboratories
    • 10.2.1. Hospital Based Laboratories
    • 10.2.2. Independent Laboratories
  • 10.3. Hospitals & Diagnostic Centers
    • 10.3.1. Private Hospitals
    • 10.3.2. Public Hospitals

11. Blood Group Typing Market, by Application

  • 11.1. Donor Screening
    • 11.1.1. Blood Typing
    • 11.1.2. Infectious Disease Screening
  • 11.2. Newborn Screening
  • 11.3. Pretransfusion Testing

12. Blood Group Typing Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Blood Group Typing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Blood Group Typing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Ortho Clinical Diagnostics, Inc.
    • 15.3.2. Abbott Laboratories
    • 15.3.3. Thermo Fisher Scientific Inc.
    • 15.3.4. Grifols, S.A.
    • 15.3.5. Bio-Rad Laboratories, Inc.
    • 15.3.6. Immucor, Inc.
    • 15.3.7. Sysmex Corporation
    • 15.3.8. BioMerieux SA
    • 15.3.9. Quotient Limited
    • 15.3.10. Fujirebio Holdings, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BLOOD GROUP TYPING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS BLOOD GROUP TYPING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA BLOOD GROUP TYPING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA BLOOD GROUP TYPING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA BLOOD GROUP TYPING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE BLOOD GROUP TYPING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST BLOOD GROUP TYPING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA BLOOD GROUP TYPING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BLOOD GROUP TYPING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN BLOOD GROUP TYPING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC BLOOD GROUP TYPING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION BLOOD GROUP TYPING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS BLOOD GROUP TYPING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 BLOOD GROUP TYPING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO BLOOD GROUP TYPING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BLOOD GROUP TYPING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. BLOOD GROUP TYPING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BLOOD GROUP TYPING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BLOOD GROUP TYPING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BLOOD GROUP TYPING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY AUTOMATED BLOOD TYPERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY AUTOMATED BLOOD TYPERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY AUTOMATED BLOOD TYPERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY AUTOMATED BLOOD TYPERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY AUTOMATED BLOOD TYPERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY AUTOMATED BLOOD TYPERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY GEL CARD ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY GEL CARD ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY GEL CARD ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY GEL CARD ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY GEL CARD ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY GEL CARD ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY ANTISERA REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY ANTISERA REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY ANTISERA REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY ANTISERA REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY ANTISERA REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY ANTISERA REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY REAGENT RED BLOOD CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY REAGENT RED BLOOD CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY REAGENT RED BLOOD CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY REAGENT RED BLOOD CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY REAGENT RED BLOOD CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY REAGENT RED BLOOD CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY SCREENING CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY SCREENING CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY SCREENING CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY SCREENING CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY SCREENING CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY SCREENING CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY LIS INTEGRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY LIS INTEGRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY LIS INTEGRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY LIS INTEGRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY LIS INTEGRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY LIS INTEGRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY SUPPORT & MAINTENANCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY SUPPORT & MAINTENANCE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY SUPPORT & MAINTENANCE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY SUPPORT & MAINTENANCE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY SUPPORT & MAINTENANCE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY SUPPORT & MAINTENANCE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY GEL CENTRIFUGATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY GEL CENTRIFUGATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY GEL CENTRIFUGATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY GEL CENTRIFUGATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY GEL CENTRIFUGATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY GEL CENTRIFUGATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY MICROPLATE AGGLUTINATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY MICROPLATE AGGLUTINATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY MICROPLATE AGGLUTINATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY MICROPLATE AGGLUTINATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY MICROPLATE AGGLUTINATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY MICROPLATE AGGLUTINATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PCR, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY REAL-TIME PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY REAL-TIME PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY REAL-TIME PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY REAL-TIME PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY BLOOD BANKS, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY BLOOD BANKS, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY BLOOD BANKS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY BLOOD BANKS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY BLOOD BANKS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY BLOOD BANKS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY BLOOD BANKS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY BLOOD BANKS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY GOVERNMENT BLOOD BANKS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY GOVERNMENT BLOOD BANKS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY GOVERNMENT BLOOD BANKS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY GOVERNMENT BLOOD BANKS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY GOVERNMENT BLOOD BANKS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY GOVERNMENT BLOOD BANKS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PRIVATE BLOOD BANKS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PRIVATE BLOOD BANKS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PRIVATE BLOOD BANKS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PRIVATE BLOOD BANKS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PRIVATE BLOOD BANKS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PRIVATE BLOOD BANKS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY CLINICAL LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY CLINICAL LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY CLINICAL LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY CLINICAL LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY CLINICAL LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY HOSPITAL BASED LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY HOSPITAL BASED LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY HOSPITAL BASED LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY HOSPITAL BASED LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY HOSPITAL BASED LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY HOSPITAL BASED LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY DONOR SCREENING, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY DONOR SCREENING, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY DONOR SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY DONOR SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY DONOR SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY DONOR SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY DONOR SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY DONOR SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY BLOOD TYPING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY BLOOD TYPING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY BLOOD TYPING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY BLOOD TYPING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY BLOOD TYPING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY BLOOD TYPING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY INFECTIOUS DISEASE SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY NEWBORN SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY NEWBORN SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY NEWBORN SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY NEWBORN SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY NEWBORN SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY NEWBORN SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PRETRANSFUSION TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PRETRANSFUSION TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PRETRANSFUSION TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PRETRANSFUSION TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PRETRANSFUSION TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY PRETRANSFUSION TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL BLOOD GROUP TYPING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS BLOOD GROUP TYPING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS BLOOD GROUP TYPING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS BLOOD GROUP TYPING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS BLOOD GROUP TYPING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS BLOOD GROUP TYPING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS BLOOD GROUP TYPING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS BLOOD GROUP TYPING MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS BLOOD GROUP TYPING MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS BLOOD GROUP TYPING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS BLOOD GROUP TYPING MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS BLOOD GROUP TYPING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS BLOOD GROUP TYPING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS BLOOD GROUP TYPING MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS BLOOD GROUP TYPING MARKET SIZE, BY PCR, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS BLOOD GROUP TYPING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS BLOOD GROUP TYPING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS BLOOD GROUP TYPING MARKET SIZE, BY BLOOD BANKS, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS BLOOD GROUP TYPING MARKET SIZE, BY BLOOD BANKS, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS BLOOD GROUP TYPING MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS BLOOD GROUP TYPING MARKET SIZE, BY CLINICAL LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS BLOOD GROUP TYPING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS BLOOD GROUP TYPING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS BLOOD GROUP TYPING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS BLOOD GROUP TYPING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS BLOOD GROUP TYPING MARKET SIZE, BY DONOR SCREENING, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS BLOOD GROUP TYPING MARKET SIZE, BY DONOR SCREENING, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA BLOOD GROUP TYPING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA BLOOD GROUP TYPING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA BLOOD GROUP TYPING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA BLOOD GROUP TYPING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA BLOOD GROUP TYPING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA BLOOD GROUP TYPING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA BLOOD GROUP TYPING MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA BLOOD GROUP TYPING MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA BLOOD GROUP TYPING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA BLOOD GROUP TYPING MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA BLOOD GROUP TYPING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA BLOOD GROUP TYPING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA BLOOD GROUP TYPING MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA BLOOD GROUP TYPING MARKET SIZE, BY PCR, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA BLOOD GROUP TYPING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA BLOOD GROUP TYPING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA BLOOD GROUP TYPING MARKET SIZE, BY BLOOD BANKS, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA BLOOD GROUP TYPING MARKET SIZE, BY BLOOD BANKS, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA BLOOD GROUP TYPING MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA BLOOD GROUP TYPING MARKET SIZE, BY CLINICAL LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA BLOOD GROUP TYPING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, 2018-2024 (USD MILLION)
  • TABLE 258. NORTH AMERICA BLOOD GROUP TYPING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA BLOOD GROUP TYPING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA BLOOD GROUP TYPING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA BLOOD GROUP TYPING MARKET SIZE, BY DONOR SCREENING, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA BLOOD GROUP TYPING MARKET SIZE, BY DONOR SCREENING, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA BLOOD GROUP TYPING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA BLOOD GROUP TYPING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA BLOOD GROUP TYPING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA BLOOD GROUP TYPING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA BLOOD GROUP TYPING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 268. LATIN AMERICA BLOOD GROUP TYPING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA BLOOD GROUP TYPING MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA BLOOD GROUP TYPING MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA BLOOD GROUP TYPING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 272. LATIN AMERICA BLOOD GROUP TYPING MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA BLOOD GROUP TYPING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 274. LATIN AMERICA BLOOD GROUP TYPING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA BLOOD GROUP TYPING MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA BLOOD GROUP TYPING MARKET SIZE, BY PCR, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA BLOOD GROUP TYPING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA BLOOD GROUP TYPING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA BLOOD GROUP TYPING MARKET SIZE, BY BLOOD BANKS, 2018-2024 (USD MILLION)
  • TABLE 280. LATIN AMERICA BLOOD GROUP TYPING MARKET SIZE, BY BLOOD BANKS, 2025-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA BLOOD GROUP TYPING MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 282. LATIN AMERICA BLOOD GROUP TYPING MARKET SIZE, BY CLINICAL LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA BLOOD GROUP TYPING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, 2018-2024 (USD MILLION)
  • TABLE 284. LATIN AMERICA BLOOD GROUP TYPING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, 2025-2032 (USD MILLION)
  • TABLE 285. LATIN AMERICA BLOOD GROUP TYPING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 286. LATIN AMERICA BLOOD GROUP TYPING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA BLOOD GROUP TYPING MARKET SIZE, BY DONOR SCREENING, 2018-2024 (USD MILLION)
  • TABLE 288. LATIN AMERICA BLOOD GROUP TYPING MARKET SIZE, BY DONOR SCREENING, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA BLOOD GROUP TYPING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA BLOOD GROUP TYPING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA BLOOD GROUP TYPING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA BLOOD GROUP TYPING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA BLOOD GROUP TYPING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA BLOOD GROUP TYPING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA BLOOD GROUP TYPING MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA BLOOD GROUP TYPING MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA BLOOD GROUP TYPING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA BLOOD GROUP TYPING MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA BLOOD GROUP TYPING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE, MIDDLE EAST & AFRICA BLOOD GROUP TYPING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE, MIDDLE EAST & AFRICA BLOOD GROUP TYPING MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE, MIDDLE EAST & AFRICA BLOOD GROUP TYPING MARKET SIZE, BY PCR, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE, MIDDLE EAST & AFRICA BLOOD GROUP TYPING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE, MIDDLE EAST & AFRICA BLOOD GROUP TYPING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE, MIDDLE EAST & AFRICA BLOOD GROUP TYPING MARKET SIZE, BY BLOOD BANKS, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE, MIDDLE EAST & AFRICA BLOOD GROUP TYPING MARKET SIZE, BY BLOOD BANKS, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE, MIDDLE EAST & AFRICA BLOOD GROUP TYPING MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE, MIDDLE EAST & AFRICA BLOOD GROUP TYPING MARKET SIZE, BY CLINICAL LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE, MIDDLE EAST & AFRICA BLOOD GROUP TYPING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE, MIDDLE EAST & AFRICA BLOOD GROUP TYPING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPE, MIDDLE EAST & AFRICA BLOOD GROUP TYPING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPE, MIDDLE EAST & AFRICA BLOOD GROUP TYPING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 313. EUROPE, MIDDLE EAST & AFRICA BLOOD GROUP TYPING MARKET SIZE, BY DONOR SCREENING, 2018-2024 (USD MILLION)
  • TABLE 314. EUROPE, MIDDLE EAST & AFRICA BLOOD GROUP TYPING MARKET SIZE, BY DONOR SCREENING, 2025-2032 (USD MILLION)
  • TABLE 315. EUROPE BLOOD GROUP TYPING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 316. EUROPE BLOOD GROUP TYPING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 317. EUROPE BLOOD GROUP TYPING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 318. EUROPE BLOO